Notably, in colorectal cancer, BRAF inhibitors show limited efficacy, potentially due to the feedback activation of EGFR [54], whereas ectopic expression of EGFR in melanoma cells has been shown to elicit resistance to BRAF inhibitors [55] (supplementary material, Figure S4A). Here, EGFR is linked to colorectal cancer.